Loading...
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Dennis, Michael Davies, Michelle Oliver, S D'Souza, R Pike, L Stockman, P
Dennis, Michael
Davies, Michelle
Oliver, S
D'Souza, R
Pike, L
Stockman, P
Citations
Altmetric:
Abstract
Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK), metabolic and excretion profiles of barasertib and barasertib-hQPA were characterized in this open-label Phase I study.
Description
Date
2012-09
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 327.93 KB
Keywords
Type
Article
Citation
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. 2012, 70 (3):461-9 Cancer Chemother Pharmacol